Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP290
引用
收藏
页码：S224 / S224
页数：1
相关论文
共 50 条
  • [41] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [42] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [43] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [44] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [45] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
  • [46] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Staanum, Peter Frohlich
    Frellsen, Anders Floor
    Olesen, Marie Louise
    Iversen, Peter
    Arveschoug, Anne Kirstine
    EJNMMI PHYSICS, 2021, 8 (01)
  • [47] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Peter Frøhlich Staanum
    Anders Floor Frellsen
    Marie Louise Olesen
    Peter Iversen
    Anne Kirstine Arveschoug
    EJNMMI Physics, 8
  • [48] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [49] Data collection procedures for bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE on neuroendocrine tumors
    Frederiksen, M. H. B.
    Klausen, T. L.
    de Nijs, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S631 - S631
  • [50] Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)
    Badawy, Mohmed
    Johnson, Geoffrey B.
    Hobday, Timothy
    Packard, Annie T.
    Jain, Manoj
    Halfdanarson, Thorvardur R.
    Young, Jason R.
    Thorpe, Matthew P.
    Eiring, Rachel A.
    Kendi, Ayse Tuba
    PANCREAS, 2022, 51 (03) : E42 - E42
12345